RT Book, Section A1 Townes, Tim M. A1 Cavazzana, Marina A2 Gladwin, Mark T. A2 Kato, Gregory J. A2 Novelli, Enrico M. SR Print(0) ID 1179345611 T1 Gene Therapy for Sickle Cell Disease T2 Sickle Cell Disease YR 2021 FD 2021 PB McGraw-Hill Education PP New York, NY SN 9781260458596 LK hemonc.mhmedical.com/content.aspx?aid=1179345611 RD 2024/04/24 AB The sickle mutation is a transversion from A to T in the sixth codon of the β-globin gene. The sixth codon is normally GAG, which encodes glutamic acid, but the transversion results in GTG, which encodes valine. Valine forms a hydrophobic projection on the surface of the hemoglobin tetramer (α2βS2; HbS), and when HbS releases oxygen, the valine fits into a natural hydrophobic pocket on a second tetramer in a nucleation event that stimulates the polymerization of thousands of HbS tetramers. The elongated polymers interact with each other to form a 14-stranded polymer, which is one of the most interesting and destructive polymers in nature. The HbS polymers convert normally pliable red blood cells (RBCs) into fragile, rigid rods and sickle-shaped structures that occlude small vessels and that lyse and release a host of products causing extensive tissue and organ damage.1Figure 29-1 is a magnetic resonance angiography of the brain of a young sickle cell patient who has suffered a massive stroke. Her left internal carotid artery is completely occluded and, therefore, invisible in the image. She has permanent right hemiplegia. Occlusions of smaller vessels in the brain in 53% of sickle patients result in “silent infarcts,” which is a misnomer because they result in cognitive impairment.2 Pathology caused by occlusions and by extensive oxidative stress in many other tissues and organs result in a severe disease that affects 100,000 patients in the United States and millions worldwide.